The capsaicin 8% cutaneous patch is an emergent new treatment option for patients with peripheral neuropathic pain. In randomized controlled clinical studies relevant pain relief for 12 weeks was achieved in about one third of patients following a single application. The first part of this paper is a review of the pathophysiology, pharmacology, and published clinical trials with the capsaicin 8% cutaneous patch. The second part reports on outcomes of an interdisciplinary expert workshop, where new treatment results of three major German pain centers were presented and reviewed with the objectives of obtaining responder rates for different pain syndromes, assessing maintenance of effect under real-life conditions, and giving recommendations for practical care. The 12 week responder rates with pain relief of ≥ 30% were comparable in patients with mononeuropathies (37.9%) and postherpetic neuralgia (38.8%). Similar responder rates were seen in a subgroup of patients with cervical spine radiculopathy and back pain (46.7%). In HIV-associated neuropathy the responder rates were high (47.8%) but lower in patients with other polyneuropathies (17.6%). Response rates were nearly identical after 1 week (46.6%) and 4 weeks (43.3) and dropped only slightly at 12 weeks (37.4%). In a subgroup of 54 patients who underwent a second treatment, efficacy was maintained. Response rates in patients with or without lidocaine pretreatment were comparable. Treatment with the capsaicin 8% cutaneous patch was generally safe and well tolerated. The workshop panel recommended further investigation of opportunities to improve the application procedure and to perform studies on the skin penetration and distribution of capsaicin. A modified quantitative sensory testing (QST) should be developed for clinical practice in order to better understand the correlation of sensory profiles and response to capsaicin treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2013.781019DOI Listing

Publication Analysis

Top Keywords

capsaicin cutaneous
16
cutaneous patch
16
responder rates
16
response capsaicin
8
patients
8
neuropathic pain
8
pain relief
8
rates pain
8
subgroup patients
8
response rates
8

Similar Publications

The cerebellum is activated by noxious stimuli and pathological pain but its role in noxious information processing remains unknown. Here, we show that in mice, cutaneous noxious electrical stimuli induced noradrenaline (NA) release from locus coeruleus (LC) terminals in the cerebellar cortex. Bergmann glia (BG) accumulated these LC-NA signals by increasing intracellular calcium in an integrative manner ('flares').

View Article and Find Full Text PDF

Chemotherapy-induced peripheral neuropathy (CIPN) is triggered by clinically recommended chemotherapeutics. Topical capsaicin (CAP) is a US-FDA-approved therapeutic entity for the mitigation of CIPN. Besides good skin permeation efficiency, CAP concentration in a topical dermal dosage form must be controlled due to its dose-dependent therapeutic and adverse effects.

View Article and Find Full Text PDF

Activation of mouse skin mast cells and cutaneous afferent C-fiber subtypes by bee venom.

Neurosci Lett

January 2025

Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Cir, Baltimore, MD 21224, USA. Electronic address:

In mammals, many Hymenopteran stings are characterized by pain, redness, and swelling - three manifestations consistent with nociceptive nerve fiber activation. The effect of a Western honeybee (Apis mellifera) venom on the activation of sensory C-fibers in mouse skin was studied using an innervated isolated mouse skin preparation that allows for intra-arterial delivery of chemicals to the nerve terminals in the skin. Our data show that honeybee venom stimulated mouse cutaneous nociceptive-like C-fibers, with an intensity (action potential discharge frequency) similar to that seen with a maximally-effective concentration of capsaicin.

View Article and Find Full Text PDF

Objective: To investigate the benefits of topical 8% capsaicin patches for the decrease of postsurgical neuropathic pain level and area.

Methods: A systematic review with pooled analysis was conducted utilizing the PRISMA 2020 guidelines. Five commonly used databases were employed utilizing a search string made from MeSH terms and boolean operators.

View Article and Find Full Text PDF
Article Synopsis
  • * It often manifests in specific forms such as brachioradial pruritus in the forearms, notalgia paresthetica in the upper back, and anogenital itch, which can be related to spine problems.
  • * Treatment may involve topical remedies or systemic medications, but currently, there are no FDA-approved options specifically for neuropathic itch, making it essential to understand its neural causes for effective management.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!